Stock Price
34.67
Daily Change
1.10 3.28%
Monthly
8.17%
Yearly
3.71%
Q3 Forecast
32.07

EPS Reference Time Actual Consensus Previous
2026-05-25 FY2026H2 AM 0.13 0.38
2025-11-25 FY2026H1 AM 0.36 0.51 0.26
2025-05-27 FY2025H2 AM 0.38 0.34 0.04
2024-11-27 FY2025H1 0.26 0.18 0.18
2024-05-28 FY2024H2 0.04 0.24 0.27



Peers Price Chg Day Year Date
Cochlear 122.50 2.62 2.19% -61.34% Jul/29
CSL 128.07 8.55 7.15% -52.76% Jul/29
Nanosonics 3.14 0.09 2.95% -22.47% Jul/29
Ramsay Health Care 44.26 0.86 1.98% 13.84% Jul/29
ResMed 29.99 1.04 3.59% -28.80% Jul/29
Sonic Healthcare 22.72 0.71 3.23% -17.98% Jul/29
Somnomed 0.47 0 0% -30.88% Jul/28

Indexes Price Day Year Date
ASX200 8992 90.81 1.01% 2.69% Jul/29
ASX All Share 9200 87.66 0.96% 2.04% Jul/29

Fisher & Paykel Healthcare traded at 34.67 this Wednesday July 29th, increasing 1.10 or 3.28 percent since the previous trading session. Looking back, over the last four weeks, Fisher & Paykel Healthcare gained 8.17 percent. Over the last 12 months, its price rose by 3.71 percent. Looking ahead, we forecast Fisher & Paykel Healthcare to be priced at 32.07 by the end of this quarter and at 30.30 in one year, according to Trading Economics global macro models projections and analysts expectations.

Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets medical device products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea. The Company’s segment includes North America, which includes all activities controlled by entities or employees based in the United States and Canada; Europe, which includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden, Turkey and Russia, and Asia-Pacific, which includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan and Hong Kong, and Other segment includes New Zealand, Latin America, Africa, the Middle East and other countries.